Study to evaluate the safety and efficacy of Phenyramidol Tablet in the treatment of Patients suffering from acute conditions of Lumbago, Integumental pain and Musculoskeletal pain

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2010/091/000582

Enrollment

120

Registered

2010-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Acute Lumbago, Acute Integumental pain and Acute Musculoskeletal pain

Interventions

Intervention1: Phenyramidol HCl: 1 to 2 tablets, 2 to 3 times daily for 3 to 7 days Control Intervention1: NIL: NA

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of either sex between 18 to 60 years of age. 2) Patients suffering from acute conditions of Lumbago, Integumental and Musculoskeletal pain

Exclusion criteria

Exclusion criteria: 1) Any specific condition which does not justify patients inclusion in the study in the opinion of the investigator.

Design outcomes

Primary

Measure	Time frame
SafetyTimepoint: Baseline Visit and End of the Treatment	—

Secondary

Measure	Time frame
EfficacyTimepoint:	—

Countries

India

Contacts

Public ContactSakshi Pawar

None

aliya.s@vediclifesciences.com022-42025703

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026